PMV PHARMACEUTICALS, INC. Shareholders' Equity
PMV PHARMACEUTICALS, INC. (PMVP) had Shareholders' Equity of $71.50 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-14
- 2026-06-30: Stockholders' Equity Attributable to Parent $71.50M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $87.97M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $104.71M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $121.00M.
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2026-06-30 | $71.50M 10-Q · filed 2026-08-14 | |
| 2026-03-31 | $87.97M 10-Q · filed 2026-08-14 | |
| 2025-12-31 | $104.71M 10-Q · filed 2026-08-14 | |
| 2025-09-30 | $121.00M 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $140.60M 10-Q · filed 2026-08-14 | |
| 2025-03-31 | $160.11M 10-Q · filed 2026-08-14 | |
| 2024-12-31 | $176.08M 10-Q · filed 2026-08-14 | |
| 2024-09-30 | $197.91M 10-Q · filed 2025-11-12 | |
| 2024-06-30 | $214.32M 10-Q · filed 2025-11-12 | $214.31M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $212.68M 10-Q · filed 2025-11-12 | |
| 2023-12-31 | $225.69M 10-K · filed 2026-03-06 | |
| 2023-09-30 | $237.61M 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $217.81M 10-Q · filed 2024-11-07 | |
| 2023-03-31 | $230.17M 10-Q · filed 2024-11-07 | |
| 2022-12-31 | $246.03M 10-K · filed 2026-03-06 | |
| 2022-09-30 | $261.19M 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $276.97M 10-Q · filed 2023-11-09 | |
| 2022-03-31 | $291.84M 10-Q · filed 2023-11-09 | |
| 2021-12-31 | $308.56M 10-K · filed 2025-03-03 | |
| 2021-09-30 | $324.95M 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $337.85M 10-Q · filed 2022-11-08 | |
| 2021-03-31 | $348.30M 10-Q · filed 2022-11-08 | |
| 2020-12-31 | $359.12M 10-K · filed 2024-02-29 | |
| 2020-09-30 | $368.97M 10-Q · filed 2021-11-12 | |
| 2020-06-30 | -$85.01M 10-Q · filed 2021-11-12 | |
| 2020-03-31 | -$77.51M 10-Q · filed 2021-11-12 | |
| 2019-12-31 | -$70.47M 10-K · filed 2023-03-01 | |
| 2019-09-30 | -$63.66M 10-Q · filed 2020-11-13 | |
| 2019-06-30 | -$57.72M 10-Q · filed 2020-11-13 | |
| 2019-03-31 | -$51.92M 10-Q · filed 2020-11-13 | |
| 2018-12-31 | -$46.14M 10-K · filed 2022-03-01 | |
| 2017-12-31 | -$29.73M 10-K · filed 2021-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |